The current price of EPRX is $6.60 — it has decreased by 2.37% since the previous close. Data as of Nov 5, 2026.
EPRX is down 7.04% over the past week, down 14.73% over the past month and up 18.28% over the past year. The price is below its 200-day moving average of $7.28.
Analysts' average 12-month price target for EPRX is $17.50, which implies 165.15% upside from the current price. Individual estimates range from $11.00 to $25.00.
Eupraxia Pharmaceuticals Inc. has a market capitalization of $436.08M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Eupraxia Pharmaceuticals Inc. posted a loss of $0.1596 per share against an estimate of -$0.2299, beating expectations by 30.55%. Upcoming reports are listed in the earnings calendar.
Companies most comparable to Eupraxia Pharmaceuticals Inc. include SELLAS Life Sciences Group, Inc., Genfit S.A., Orchestra BioMed Holdings, Inc., Nautilus Biotechnolgy, Inc. and Cartesian Therapeutics, Inc.
In the latest trading session EPRX moved between $6.30 and $6.77, a range of 7.12% of its current price.
Over the past 52 weeks EPRX has traded between $5.29 and $9.32. The current price is 29.18% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.